amantadine has been researched along with Neuroleptic Malignant Syndrome in 38 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The following case report describes a patient developing neuroleptic malignant syndrome (NMS) secondary to the use of haloperidol given to control the patient's agitation." | 7.70 | Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. ( Guin-Renfroe, S; Meythaler, JM; Wilkinson, R, 1999) |
| "Amantadine was introduced for the pharmacological management of neuroleptic malignant syndrome (NMS) because of its beneficial effects in Parkinson's disease which were attributed to dopaminomimetic properties." | 7.68 | Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. ( Kornhuber, J; Weller, M, 1993) |
| "Amantadine, which was originally developed as an antiviral medication, functions as a dopamine agonist in the central nervous system and consequently is utilized in the treatment of Parkinson disease, drug-induced extrapyramidal reactions, and neuroleptic malignant syndrome." | 3.85 | The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status. ( Fox, J; Fryml, LD; Pelic, CG; Revuelta, GJ; Robert, S; Sahlem, G; Short, EB; Williams, KR, 2017) |
| " The following case report describes a patient developing neuroleptic malignant syndrome (NMS) secondary to the use of haloperidol given to control the patient's agitation." | 3.70 | Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. ( Guin-Renfroe, S; Meythaler, JM; Wilkinson, R, 1999) |
| "Amantadine was introduced for the pharmacological management of neuroleptic malignant syndrome (NMS) because of its beneficial effects in Parkinson's disease which were attributed to dopaminomimetic properties." | 3.68 | Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome. ( Kornhuber, J; Weller, M, 1993) |
| "We performed a case-controlled analysis on the effectiveness of dantrolene and certain dopamine agonists--bromocriptine, amantadine 3,4-dihydroxyphenylalanine, (DOPA)--for the neuroleptic malignant syndrome (NMS)." | 3.68 | Drug treatment of the neuroleptic malignant syndrome. ( Davis, JM; Janicak, PG; Sakkas, P; Wang, ZY, 1991) |
| "Amantadine is an antiparkinsonian medication scarcely associated with PHS." | 2.72 | Parkinsonism-hyperpyrexia Syndrome After Amantadine Withdrawal: Case Report and Review of the Literature. ( Dos Santos, DT; Imthon, AK; Pille, A; Schumacher-Schuh, AF; Strelow, MZ, 2021) |
| "Neuroleptic malignant syndrome is difficult to distinguish from febrile catatonia and the diagnosis can often only be made through the clinical course." | 2.39 | [The neuroleptic malignant syndrome]. ( Agelink, MW; Dammers, S; Leonhardt, M; Schär, V; Zeit, T, 1995) |
| "We report an unusual case of neuroleptic malignant syndrome that presented predominantly with autonomic instability in the form of recurrent episodes of respiratory distress." | 1.31 | Neuroleptic malignant syndrome presenting as pulmonary edema and severe bronchorrhea. ( Agrawal, M; Krishnan, P; Niranjan, S; Patel, U, 2002) |
| "Pneumonia and renal failure significantly increased the morbidity and extended the course of the illness." | 1.29 | An atypical course of neuroleptic malignant syndrome. ( Marken, PA; Schneiderhan, ME, 1994) |
| "Amantadine was introduced for the pharmacological management of NMS because of its beneficial effects in Parkinson's disease which were attributed to direct or indirect dopaminomimetic properties of amantadine." | 1.28 | A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. ( Kornhuber, J; Weller, M, 1992) |
| "Malignant Hyperthermia is a specific potentially fatal condition which occurs in susceptible individuals in response to various triggering mechanisms, of which anesthetic agents have been found to be the most common offenders." | 1.27 | [Malignant neuroleptic syndrome and malignant hyperthermia--a comparison]. ( Hippius, H; Spiess-Kiefer, C, 1986) |
| "A patient who developed neuroleptic malignant syndrome (NMS) from the use of several neuroleptic agents and the therapeutic interventions used to reverse the syndrome are described, and the clinical presentation and treatment of NMS are reviewed." | 1.27 | Diagnosis and treatment of neuroleptic malignant syndrome. ( Guerrero, RM; Shifrar, KA, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (44.74) | 18.7374 |
| 1990's | 12 (31.58) | 18.2507 |
| 2000's | 6 (15.79) | 29.6817 |
| 2010's | 2 (5.26) | 24.3611 |
| 2020's | 1 (2.63) | 2.80 |
| Authors | Studies |
|---|---|
| Dos Santos, DT | 1 |
| Imthon, AK | 1 |
| Strelow, MZ | 1 |
| Pille, A | 1 |
| Schumacher-Schuh, AF | 1 |
| Fryml, LD | 1 |
| Williams, KR | 1 |
| Pelic, CG | 1 |
| Fox, J | 1 |
| Sahlem, G | 1 |
| Robert, S | 1 |
| Revuelta, GJ | 1 |
| Short, EB | 1 |
| Brantley, E | 1 |
| Cohn, J | 1 |
| Babu, K | 1 |
| Cheung, YF | 1 |
| Hui, CH | 1 |
| Chan, JH | 1 |
| Reingardiene, D | 1 |
| Kawabata, M | 1 |
| Kubo, I | 1 |
| Suzuki, K | 1 |
| Terai, T | 1 |
| Iwama, T | 1 |
| Isobe, M | 1 |
| Strawn, JR | 1 |
| Keck, PE | 1 |
| Caroff, SN | 1 |
| Gangadhar, BN | 1 |
| Desai, NG | 1 |
| Channabasavanna, SM | 1 |
| Gómez, EA | 1 |
| Schneiderhan, ME | 1 |
| Marken, PA | 1 |
| Kornhuber, J | 4 |
| Weller, M | 4 |
| Bower, DJ | 1 |
| Chalasani, P | 1 |
| Ammons, JC | 1 |
| Dammers, S | 1 |
| Zeit, T | 1 |
| Leonhardt, M | 1 |
| Schär, V | 1 |
| Agelink, MW | 1 |
| Blümlein, G | 1 |
| Sunohara, N | 1 |
| Wilkinson, R | 1 |
| Meythaler, JM | 1 |
| Guin-Renfroe, S | 1 |
| Ito, T | 1 |
| Shibata, K | 1 |
| Watanabe, A | 1 |
| Akabane, J | 1 |
| Patel, U | 1 |
| Agrawal, M | 1 |
| Krishnan, P | 1 |
| Niranjan, S | 1 |
| Sczesni, B | 1 |
| Becker, H | 1 |
| Schröder, J | 1 |
| Bittkau, S | 1 |
| von Baumgarten, F | 1 |
| Truong, DD | 1 |
| Przuntek, H | 1 |
| Sakkas, P | 1 |
| Davis, JM | 1 |
| Janicak, PG | 1 |
| Wang, ZY | 1 |
| Spiess-Kiefer, C | 1 |
| Hippius, H | 1 |
| Lazarus, A | 3 |
| Hermesh, H | 1 |
| Sirota, P | 1 |
| Eviatar, J | 1 |
| Shalev, A | 1 |
| Munitz, H | 1 |
| Guerrero, RM | 1 |
| Shifrar, KA | 1 |
| Jee, A | 1 |
| Kumar, V | 1 |
| Abbott, RJ | 1 |
| Loizou, LA | 1 |
| Woo, J | 1 |
| Teoh, R | 1 |
| Vallance-Owen, J | 1 |
| Guzé, BH | 1 |
| Baxter, LR | 1 |
| Susman, VL | 1 |
| Addonizio, G | 1 |
| Rosse, R | 1 |
| Ciolino, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00627250] | 76 participants (Actual) | Interventional | 2003-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for amantadine and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Parkinsonism-hyperpyrexia Syndrome After Amantadine Withdrawal: Case Report and Review of the Literature.
Topics: Aged; Amantadine; Antiparkinson Agents; Female; Humans; Neuroleptic Malignant Syndrome; Parkinson Di | 2021 |
[Neuroleptic malignant syndrome].
Topics: Acute Kidney Injury; Adult; Amantadine; Bromocriptine; Carbidopa; Contraindications; Dantrolene; Dia | 2002 |
Neuroleptic malignant syndrome.
Topics: Adult; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Bromocriptine; Dantr | 2007 |
[The neuroleptic malignant syndrome].
Topics: Adult; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Benperidol; Combined Modality Therapy | 1995 |
[Toxic and adverse neurological effects of anti-parkinsonian drugs].
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Cholinergic Antagonists; Dopamine Agents; Dyskinesi | 1999 |
[Pathophysiology and therapy of malignant neuroleptic syndrome].
Topics: Amantadine; Antipsychotic Agents; Dantrolene; Dopamine; Dopamine Agents; Drug Therapy, Combination; | 1992 |
Neuroleptic malignant syndrome.
Topics: Amantadine; Brain; Bromocriptine; Dantrolene; Humans; Neuroleptic Malignant Syndrome; Prognosis | 1989 |
The neuroleptic malignant syndrome: agent and host interaction.
Topics: Adolescent; Adult; Aftercare; Aged; Akathisia, Drug-Induced; Amantadine; Antiparkinson Agents; Antip | 1986 |
Neuroleptic malignant syndrome.
Topics: Adult; Amantadine; Animals; Body Temperature; Bromocriptine; Dantrolene; Diagnosis, Differential; Fe | 1986 |
Current concepts. Neuroleptic malignant syndrome.
Topics: Amantadine; Basal Ganglia Diseases; Bromocriptine; Catatonia; Dantrolene; Diagnosis, Differential; D | 1985 |
28 other studies available for amantadine and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status.
Topics: Aged; Amantadine; Catatonia; Delirium; Dopamine Agents; Electroconvulsive Therapy; Humans; Male; Mid | 2017 |
Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.
Topics: Amantadine; Antipsychotic Agents; Diagnosis, Differential; Drug Therapy, Combination; Female; Fluid | 2009 |
Parkinsonism-hyperpyrexia syndrome due to abrupt withdrawal of amantadine.
Topics: Amantadine; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease, Secondary; | 2011 |
'Tako-Tsubo cardiomyopathy' associated with syndrome malin: reversible left ventricular dysfunction.
Topics: 3-Iodobenzylguanidine; Aged; Amantadine; Antidepressive Agents, Tricyclic; Cardiomyopathies; Coronar | 2003 |
Amantadine in the neuroleptic malignant syndrome.
Topics: Adult; Amantadine; Basal Ganglia Diseases; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome | 1984 |
[Extrapyramidal reactions and neuroleptic malignant syndrome].
Topics: Adult; Amantadine; Basal Ganglia Diseases; Dantrolene; Haloperidol; Humans; Male; Neuroleptic Malign | 1984 |
An atypical course of neuroleptic malignant syndrome.
Topics: Amantadine; Bromocriptine; Dantrolene; Drug Therapy, Combination; Emergency Service, Hospital; Human | 1994 |
Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.
Topics: Adult; Amantadine; Antipsychotic Agents; Depressive Disorder; Female; Glutamates; Glutamic Acid; Hum | 1993 |
Withdrawal-induced neuroleptic malignant syndrome.
Topics: Aged; Amantadine; Humans; Male; Neuroleptic Malignant Syndrome; Parkinson Disease; Substance Withdra | 1994 |
Amantadine withdrawal and neuroleptic malignant syndrome.
Topics: Amantadine; Bromocriptine; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Subs | 1993 |
[Successful use of amantadine in treatment of malignant neuroleptic syndrome].
Topics: Adult; Amantadine; Antiparkinson Agents; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; | 1997 |
Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury.
Topics: Adolescent; Amantadine; Brain Injuries; Dopamine Agents; Dopamine Antagonists; Fever; Haloperidol; H | 1999 |
Neuroleptic malignant syndrome following withdrawal of amantadine in a patient with influenza A encephalopathy.
Topics: Adolescent; Amantadine; Antiviral Agents; Brain Diseases; Dopamine Antagonists; Humans; Influenza, H | 2001 |
Neuroleptic malignant syndrome presenting as pulmonary edema and severe bronchorrhea.
Topics: Amantadine; Antipsychotic Agents; Bromocriptine; Dantrolene; Dopamine Agonists; Dopamine Antagonists | 2002 |
A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome.
Topics: Amantadine; Humans; Models, Biological; Muscle Spasticity; Neuroleptic Malignant Syndrome; Receptors | 1992 |
[Diagnostic and therapeutic aspects of neuroleptic malignant syndrome based on 12 cases].
Topics: Adult; Amantadine; Antipsychotic Agents; Bromocriptine; Dantrolene; Depressive Disorder; Diazepam; D | 1991 |
Drug treatment of the neuroleptic malignant syndrome.
Topics: Amantadine; Bromocriptine; Dantrolene; Dihydroxyphenylalanine; Dopamine Agents; Humans; Neuroleptic | 1991 |
[Malignant neuroleptic syndrome and malignant hyperthermia--a comparison].
Topics: Adult; Amantadine; Bromocriptine; Calcium; Cross-Sectional Studies; Dantrolene; Female; Humans; Ion | 1986 |
Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine.
Topics: Aged; Amantadine; Dementia; Drug Therapy, Combination; Haloperidol; Humans; Male; Neuroleptic Malign | 1989 |
Diagnosis and treatment of neuroleptic malignant syndrome.
Topics: Adolescent; Amantadine; Animals; Bromocriptine; Dantrolene; Electroconvulsive Therapy; Female; Human | 1988 |
Amantadine in neuroleptic malignant syndrome.
Topics: Amantadine; Humans; Neuroleptic Malignant Syndrome | 1987 |
A case of neuroleptic malignant syndrome treated with diazepam.
Topics: Aged; Amantadine; Diazepam; Humans; Male; Neuroleptic Malignant Syndrome; Substance Withdrawal Syndr | 1987 |
Therapy of neuroleptic malignant syndrome.
Topics: Amantadine; Bromocriptine; Carbidopa; Combined Modality Therapy; Dantrolene; Diazepam; Dose-Response | 1986 |
Neuroleptic malignant syndrome successfully treated with amantidine.
Topics: Adult; Amantadine; Female; Haloperidol; Humans; Neuroleptic Malignant Syndrome | 1986 |
Assessing treatment of neuroleptic malignant syndrome.
Topics: Amantadine; Bromocriptine; Cortisone; Drug Therapy, Combination; Humans; Neuroleptic Malignant Syndr | 1986 |
Neuroleptic malignant syndrome and amantadine withdrawal.
Topics: Acute Disease; Amantadine; Basal Ganglia Diseases; Female; Humans; Middle Aged; Neuroleptic Malignan | 1985 |
Dopamine agonists and neuroleptic malignant syndrome.
Topics: Alzheimer Disease; Amantadine; Basal Ganglia Diseases; Bromocriptine; Dantrolene; Humans; Male; Midd | 1985 |
[Neuroleptic malignant syndrome. A case associated with amantadine withdrawal].
Topics: Amantadine; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Substance Withdrawal Syndro | 1985 |